Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P060037/S099

NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knee System

Zimmer, Inc. · Decision date Sep 24, 2026

MEDTECHLEDGER EXPLANATIONP060037/S099

What did the FDA decide?

The FDA recorded decision OK30 on 2026-09-24 for P060037/S099, a 30-Day Notice submitted by Zimmer, Inc. for the NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knee System. The notice covers a manufacturing process change: introduction of an Elma 3-Stage Parts Washer for the system's femoral components at the Zimmer facility in Warsaw, Indiana. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier.

This action concerns a supplement to an existing premarket approval rather than a new approval of the knee system. The device category is a semi-constrained, metal/polymer, mobile-bearing patellofemoral-tibial knee prosthesis under product code NJL, in the orthopedic specialty. The source record contains no documents, so the notice's technical content, cleaning validation data and any conditions attached to the decision are not available here and remain unknown.

Whether the parts-washer change alters residue limits, cleaning validation expectations or other manufacturing controls cannot be determined from the available fields, and no clinical or legal conclusion is drawn.

FDA approval order statement

introduction of Elma 3-Stage Parts Washer for the femoral components of the NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knee System at the Zimmer Inc. facility in Warsaw, Indiana
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P060037/S099
Regulatory pathway
PMA supplement
Applicant
Zimmer, Inc.
Product code
NJL
Decision code
OK30
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.

Applicant
Zimmer, Inc.
Product code
NJL
FDA device class
3

For the original device and its historical approval scope, see PMA P060037. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P060037 · Original PMA

    NEXGEN LPS-FLEX MOBILE AND LPS-MOBILE BEARING KNEE SYSTEM

  2. P060037/S099 received

    Application receipt date recorded by FDA.

  3. P060037/S099 · FDA decision

    30-Day Notice

  4. P060037/S100 · Related supplement

    NexGen LPS-Flex/LPS Mobile Bearing Knee System

Timeline entries are records held by MedtechLedger for P060037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060037

Product / regulatory recordCompanyPathwayDecision dateSource
Zimmer, Inc.PMA approvalDec 10, 2007FDA
Zimmer, Inc.PMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code NJL

Product / regulatory recordCompanyPathwayDecision dateSource
LCS Knee SystemP830055/S378
Depuy, Inc.PMA supplementOct 27, 2026FDA
Depuy, Inc.PMA supplementOct 27, 2026FDA
Depuy, Inc.PMA supplementOct 9, 2026FDA
Depuy, Inc.PMA supplementOct 8, 2026FDA
Depuy, Inc.PMA supplementOct 5, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Zimmer, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
P.O. Box 708, Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records